Glenmark Life Sciences Ltd (BOM:543322, Financial) is set to release its Q2 2025 earnings on Oct 25, 2024. The consensus estimate for Q2 2025 revenue is $5.78 billion, and the earnings are expected to come in at $10 per share. The full year 2025's revenue is expected to be $25.26 billion and the earnings are expected to be $41.54 per share. More detailed estimate data can be found on the Forecast page.
Glenmark Life Sciences Ltd (BOM:543322, Financial) Estimates Trends
Revenue estimates for Glenmark Life Sciences Ltd (BOM:543322) have declined from $25.79 billion to $25.26 billion for the full year 2025 and from $29.54 billion to $28.87 billion for 2026 over the past 90 days. Earnings estimates for Glenmark Life Sciences Ltd (BOM:543322) have declined from $44.87 per share to $41.54 per share for the full year 2025 and from $51.41 per share to $48.55 per share for 2026 over the past 90 days.
Glenmark Life Sciences Ltd (BOM:543322, Financial) Reported History
In the previous quarter of 2024-06-30, Glenmark Life Sciences Ltd's (BOM:543322) actual revenue was $5.89 billion, which beat analysts' revenue expectations of $5.76 billion by 2.19%. Glenmark Life Sciences Ltd's (BOM:543322) actual earnings were $9.08 per share, which beat analysts' earnings expectations of $9 per share by 0.89%. After releasing the results, Glenmark Life Sciences Ltd (BOM:543322) was up by 2.62% in one day.
Glenmark Life Sciences Ltd (BOM:543322, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 6 analysts, the average target price for Glenmark Life Sciences Ltd (BOM:543322) is $1084.33 with a high estimate of $1295 and a low estimate of $790. The average target implies an upside of 1.02% from the current price of $1073.35.
Based on GuruFocus estimates, the estimated GF Value for Glenmark Life Sciences Ltd (BOM:543322, Financial) in one year is $784.92, suggesting a downside of -26.87% from the current price of $1073.35.
Based on the consensus recommendation from 6 brokerage firms, Glenmark Life Sciences Ltd's (BOM:543322, Financial) average brokerage recommendation is currently 2.2, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
